---
schema_version: "secwatch.filing_event.v1"
accession: "0001811764-23-000031"
form_type: "8-K"
ticker: null
cik: "0001811764"
company_name: "POINT Biopharma Global Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:10:25.664610+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# POINT Biopharma Global auditor Armanino resigns; Deloitte & Touche appointed as new independent auditor

## Summary
- Armanino resigned as auditor effective upon filing of Q2 2023 10-Q due to its decision to cease public company audit services.
- No disagreements or reportable events between the Company and Armanino during the past two fiscal years or subsequent interim period.
- Audit Committee and Board approved engagement of Deloitte & Touche as independent auditor for fiscal year ending December 31, 2023.
- No prior consultations with Deloitte on accounting principles, transactions, or audit opinions during the prior two years.
- Armanino filed a letter with the SEC agreeing with the Company's statements regarding the resignation.

## SEC filing metadata
- accession: 0001811764-23-000031
- form_type: 8-K
- cik: 0001811764
- company_name: POINT Biopharma Global Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811764/000181176423000031/0001811764-23-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811764/000181176423000031/pnt-20230728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001811764-23-000031
- JSON: https://secwatch.observer/filing/0001811764-23-000031.json
- Plain text: https://secwatch.observer/filing/0001811764-23-000031.txt

## Key facts
- Auditor Changes
  POINT Biopharma Global Inc. engaged Deloitte & Touche LLP as its auditor.
  - Action: engagement
  - Auditor: Deloitte & Touche LLP
  source text: On August 3, 2023, the Audit Committee approved, and the Board ratified, the engagement of Deloitte & Touche LLP (“Deloitte”) and appointed Deloitte as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the fiscal year ending December 31, 2023, subject to the execution of an engagement letter.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000181176423000031/0001811764-23-000031-index.htm
- Auditor Changes
  Armanino LLP resigned as auditor of POINT Biopharma Global Inc..
  - Action: resignation
  - Auditor: Armanino LLP
  - Successor: Deloitte & Touche LLP
  source text: On July 28, 2023, POINT Biopharma Global Inc. (the “Company”) was notified by Armanino LLP (“Armanino”), the Company’s independent registered public accounting firm, of its decision to cease providing financial statement audit services to public companies and therefore it would be resigning as the Company’s independent registered public accounting firm.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811764/000181176423000031/0001811764-23-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.